



## **Availability and consultation of the information related to the Annual General Meeting to be held on June 27, 2018**

**Paris, June 6, 2018** – 6.00PM CET - Pixium Vision (FR0011950641 - PIX), a company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, informs its shareholders that the Annual General Meeting of the Company will be held on Wednesday June 27, 2018, at 9.00 AM CET at the headquarter of Pixium Vision, 74 rue du faubourg Saint Antoine in Paris (75012).

The prior notice of the Annual General Meeting containing the agenda, the draft resolutions presented by the Board of Directors for agreement by the shareholders was published in the BALO n°62 (Bulletin des Annonces Légales et Obligatoires) on May 23, 2018 and the convening notice will be published in the BALO on June 11, 2018.

The information regarding the Annual General Meeting mentioned in article R. 225-73-1 of the French commercial Code can be found as from today on the Company's website [www.pixium-vision.com](http://www.pixium-vision.com), under « Investors », « Shareholder's General Meeting ».

The documents and information mentioned in articles R.225-81 and R.225-83 of the French commercial Code can be sent to shareholders upon request to the Company.

Shareholders will also be able to consult the documents (including Registration Document) at the Company's registered office located in Paris (75012), 74, rue du Faubourg Saint Antoine, during 15 days prior to the Annual General Meeting.

## Contacts

### Pixium Vision

Didier Laurens, CFO

[investors@pixium-vision.com](mailto:investors@pixium-vision.com)

+33 1 76 21 47 68



@PixiumVision

### Media Relations

France: Newcap Media

Annie-Florence Loyer - [afloyer@newcap.fr](mailto:afloyer@newcap.fr)


+33 1 44 71 00 12 / +33 6 88 20 35 59

Léa Jacquin - [ljacquin@newcap.fr](mailto:ljacquin@newcap.fr)

+33 1 44 71 94 94

## ABOUT PIXIUM VISION

Pixium Vision's mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention as well as a rehabilitation period. Following the CE mark for its first bionic retinal implant systems, IRIS®II, Pixium Vision is now conducting a clinical study<sup>1</sup> in Human with PRIMA, its new generation sub-retinal miniaturized photovoltaic wireless implant system, for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners spanning across the prestigious Vision research institutions including the Institut de la Vision in Paris, the Stanford University in California, Moorfields Eye Hospital in London, and Institute of Ocular Microsurgery (IMO) in Barcelona. The company is EN ISO 13485 certified and qualifies as "Entreprise Innovante" par Bpifrance.

For more information, please visit:  [www.pixium-vision.com](http://www.pixium-vision.com);

And follow us on:  @PixiumVision;  [www.facebook.com/pixiumvision](http://www.facebook.com/pixiumvision)

 [www.linkedin.com/company/pixium-vision](http://www.linkedin.com/company/pixium-vision)



Pixium Vision is listed on Euronext Paris (Compartment C). Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.

Pixium Vision is included in the Euronext CAC All Shares index

Euronext ticker: PIX - ISIN: FR0011950641 – Reuters: PIX.PA – Bloomberg: PIX:FP

## Disclaimer:

*This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.*

*Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.*

*For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company's Registration Document filed with the AMF on March 26, 2018 which can be found on the websites of the AMF - AMF ([www.amf-france.org](http://www.amf-france.org)) and of Pixium Vision ([www.pixium-vision.com](http://www.pixium-vision.com)).*

*IRIS® is a trademark of Pixium-Vision SA*